326 related articles for article (PubMed ID: 31433680)
21. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
22. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
23. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
24. Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.
Kaine J; Song X; Kim G; Hur P; Palmer JB
J Manag Care Spec Pharm; 2019 Jan; 25(1):122-132. PubMed ID: 29694270
[TBL] [Abstract][Full Text] [Related]
25. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
Feldman SR; Zhao Y; Shi L; Tran MH
J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
Bradford Rice J; White A; Lopez A; Galebach P; Schepman P; Popelar B; Philbin M
J Med Econ; 2016 Jul; 19(7):649-54. PubMed ID: 26850074
[TBL] [Abstract][Full Text] [Related]
27. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.
Feldman SR; Zhao Y; Shi L; Tran MH; Lu J
Arthritis Care Res (Hoboken); 2015 May; 67(5):708-17. PubMed ID: 25303478
[TBL] [Abstract][Full Text] [Related]
28. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
29. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
Joyce AT; Smith P; Khandker R; Melin JM; Singh A
J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
[TBL] [Abstract][Full Text] [Related]
30. Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study.
Hitchon CA; Walld R; Peschken CA; Bernstein CN; Bolton JM; El-Gabalawy R; Fisk JD; Katz A; Lix LM; Marriott J; Patten SB; Sareen J; Singer A; Marrie RA
Arthritis Care Res (Hoboken); 2021 Jan; 73(1):90-99. PubMed ID: 32702203
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
32. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
[No Abstract] [Full Text] [Related]
33. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
34. Assessment of economic burden of fatigue in adults with multiple sclerosis: An analysis of US National Health and Wellness Survey data.
Le HH; Ken-Opurum J; LaPrade A; Maculaitis MC; Sheehan JJ
Mult Scler Relat Disord; 2022 Sep; 65():103971. PubMed ID: 35843012
[TBL] [Abstract][Full Text] [Related]
35. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
36. Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA.
Estes SJ; Soliman AM; Zivkovic M; Chopra D; Zhu X
Adv Ther; 2020 Jun; 37(6):2777-2791. PubMed ID: 32399813
[TBL] [Abstract][Full Text] [Related]
37. Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs.
Chen CI; Wang L; Wei W; Yuce H; Phillips K
Rheumatol Adv Pract; 2018; 2(1):rky005. PubMed ID: 31431954
[TBL] [Abstract][Full Text] [Related]
38. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
Cai B; Said Q; Li X; Li FY; Arcona S
J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
[No Abstract] [Full Text] [Related]
39. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis.
Ethgen O; Kahler KH; Kong SX; Reginster JY; Wolfe F
J Rheumatol; 2002 Jun; 29(6):1147-55. PubMed ID: 12064827
[TBL] [Abstract][Full Text] [Related]
40. Clinical and economic burden of breakthrough seizures.
Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
